RESEARCH WATCH · 10 OCTOBER 2026 · EVENING UPDATE · 4 MIN READ
Changing experience.
Testing outcomes.
Can mindfulness help sustain psychedelic therapy’s benefits? Can re-engineered retinal cells recover aspects of vision?
Two distinct human research developments: a planned depression study and preliminary visual-function results. Their evidence status differs.
EMPIRICAL RESEARCH PROGRAMME · NO NEW TREATMENT RESULTS
Testing the contribution of mindfulness
What changed: USC described EVIDENT-MAP, a planned study of 80 adults with depression and no previous psychedelic or meditation experience. It expands work in healthy volunteers to a clinical population. The October announcement is new; the funding began in May.
Design: Half the participants will receive psilocybin therapy alone and half will also complete eight weeks of mindfulness training. Both receive two psilocybin sessions, preparation and integration support. Planned assessments include psychological measures, EEG, MRI, biological samples and wearable data.
Why it matters: The comparison asks whether a structured contemplative practice adds benefit to the therapy. ARPA-H also identifies goals around depression and suicidality markers, with de-identified data entering its EVIDENT repository.
Evidence status & limitations
Research plan, not evidence of efficacy. No outcomes, effect estimates or uncertainty intervals for the depression cohort were reported. The announcement does not specify randomisation or masking; a registry entry for this expanded cohort was not verified in this review. Additional contact time, participant expectations and adherence will matter. Neither a mindfulness-only nor a placebo arm is described. The planned comparison cannot establish every component’s independent effect. Institutional comments about the earlier healthy-volunteer work are not results from this depression study.
EMPIRICAL RESEARCH · HUMAN PHASE I STUDY · PEER REVIEWED
Recovering aspects of visual function
What changed: José-Alain Sahel, Botond Roska and colleagues reported a cohort of 10 people with blindness due to advanced retinitis pigmentosa, extending their earlier single-patient report. Gene therapy makes surviving retinal ganglion cells light-sensitive; special goggles provide the activating light.
Results: Light sensitivity increased in seven participants, by factors ranging from 2.0 to 62.3. Six met the authors’ clinically meaningful threshold. Some participants improved in object-related tasks. Normal vision was not restored.
Why it matters: The cohort offers preliminary evidence that the approach can recover some function beyond one individual, even after advanced retinal degeneration.
Evidence strength & limitations
Preliminary human evidence. This open-label study primarily assessed safety, with no randomised control group. The clinically meaningful light-sensitivity threshold was not prespecified in the protocol. Ten participants leave substantial uncertainty; reported ranges are not confidence intervals. There were 34 ocular adverse events in nine participants: 23 mild, 10 moderate and one severe transient arterial occlusion that resolved within minutes. These findings do not establish rare-event or long-term safety. GenSight Biologics funded the study. Larger controlled studies and independent replication remain necessary.
Optogenetic Therapy for Restoring Aspects of Visual Function. DOI: 10.1056/NEJMoa2602215. Assessment based on the published abstract and institutional report; no independent participant-data reanalysis.
AKASHICNET INTERPRETATION · OPEN QUESTIONS
Experience, lasting change and care
For BQ011, the USC programme offers a testable question about integration: can practice help turn a temporary experience into durable benefit? Depression symptoms, compassionate behaviour and planetary flourishing require separate measurements. No such connection has been demonstrated by this announcement.
The vision study concerns sensory access and function. It does not resolve the nature of subjective experience, consciousness beyond the individual or an Akashic field. Big Question evidence statuses remain unchanged.
- Will the mindfulness comparison control for attention, expectations and additional support?
- Which benefits persist, for whom, and after how long?
- Can visual-function improvements reproduce under blinded assessment and prespecified criteria?
These are independent discussion prompts for TSC2026 attendees, not claims that either project is on the conference programme.
